22 September 2020
Russia’s Healthcare Ministry has allowed the use of two favipiravir preparations for outpatient treatment of the novel coronavirus infection. Earlier these pharmaceuticals were only permitted for use in a hospital setting, the press service of the Healthcare Ministry reported.
“Russia’s Healthcare Ministry introduced changes to the registration certificates of two domestic preparations for the treatment of the novel coronavirus infection (COVID-19) with the international nonproprietary name (INN) of favipiravir, allowing their use on the outpatient basis. Earlier the preparations could be used exclusively for hospital treatment of patients,” the statement said.
Favipiravir was developed in Japan as a flu medicine and was approved for use in 2014. Preparations on its basis are produced under Avigan, Areplivir, or Favilavir brand names. In Russia, it is known as Avifavir. Avifavir was officially registered by the Russian Healthcare Ministry as the first drug against the coronavirus at the end of May 2020. It has also become the first registered anti-coronaviral drug worldwide.
PrintNovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Grand finale from a veritable stalwart of neuroscience
09 November 2023
Battle of pharma advocates – in search of the ideal migraine therapy
09 November 2023
Positive study results in 298 patients with obstructive sleep apnea (OSA)
15 March 2024
Rapid pseudomonas aeruginosa detection method developed
15 March 2024
Developing new treatment regimens for HIV
14 March 2024
Life sci marketing budgets boomed in 2023, led by spending on trade shows and websites, survey finds
14 March 2024